卡格列净对老年2型糖尿病患者血管功能的影响  

Effect of Canagliflozin on Vascular Function in Elderly Patients with Type 2 Diabetes

作　　者：吴晶莹[1] 王耀国[1] 周昆林[1] 蔡银链[1] 陈啸峰[1] WU Jing-ying;WANG Yao-guo;ZHOU Kun-lin;CAI Yin-lian;CHEN Xiao-feng(The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属第二医院,福建泉州362000

出　　处：《海峡药学》2023年第1期110-115,共6页Strait Pharmaceutical Journal

基　　金：福建省自然科学基金资助项目(2020J01224、2022J01779);福建省教育厅中青年教师教育科研项目(JAT190218)。

摘　　要：目的研究卡格列净对老年2型糖尿病患者血管功能的影响。方法收集就诊我院的老年2型糖尿病患者143例。入选者入选前3个月使用二甲双胍和或胰岛素治疗。随机分为:卡格列净组即在原降糖方案基础上联合卡格列净;对照组继续原降糖方案治疗。随访6个月,收集治疗前后两组的一般临床资料并检测脉压、臂踝脉搏波传导速度(baPWV)、踝臂血压指数(ABI)及颈动脉内膜中层厚度(CIMT)等指标。结果①两组治疗前的一般临床资料、脉压、baPWV、ABI及CIMT差异无统计学意义(P>0.05)。②两组治疗后的血糖、HbA1c均较治疗前显著降低(P<0.05);卡格列净组治疗后的BMI、血压、脉压、baPWV和CIMT显著低于治疗前及对照组治疗后(P<0.05),ABI显著高于治疗前及对照组治疗后(P<0.05)。结论卡格列净显著改善老年2型糖尿病患者血管功能,延缓动脉硬化。OBJECTIVE To study the effect of canagliflozin on vascular function in elderly patients with type 2 diabetes.METHODS A total of 143 elderly patients with type 2 diabetes who visited our hospital were collected.Enrollees were treated with metformin and/or insulin alone for 3 months before enrollment.Enrollees were randomly divided into:canagliflozin group combined with canagliflozin based on the original hypoglycemic regimen;control group continued the original hypoglycemic regimen.The patients were followed up for 6 months.The general clinical data of the two groups of patients were collected before and after treatment,and the pulse pressure,brachial-ankle pulse wave velocity(baPWV),ankle-brachial blood pressure index(ABI)and carotid intima-media thickness(CIMT)were detected.RESULTS①There was no significant difference in general clinical data,pulse pressure,baPWV,ABI and CIMT between the two groups before treatment(P>0.05).②Blood glucose and HbA1c in the two group after treatment were significantly lower than those before treatment(P<0.05);BMI,blood pressure,pulse pressure,baPWV and CIMT in canagliflozin group after treatment were significantly lower than those before treatment and in control group after treatment(P<0.05).ABI in canagliflozin group after treatment was significantly increased compared with that before treatment and in the control group after treatment(P<0.05).CONCLUSION Canagliflozin can significantly improve vascular function and delay arteriosclerosis in elderly patients with type 2 diabetes.

关 键 词：钠-葡萄糖共转运体2抑制剂 卡格列净 2型糖尿病 血管功能 

分 类 号：R969.4[医药卫生—药理学]